Key Points
NEW DELHI: The Indian pharmaceutical market has shown robust value growth of 9.2% with major therapies recording a double-digit increase in December...
Among the top therapies, cardiac, anti-infectives and neuro/central nervous system have shown a relatively stronger volume growth last month, according to data from research firm PharmaTrac..
Antibiotic drug Augmentin and anti-diabetes Glycomet GP continued to be the top-selling medicine brands...
All the three growth levers - new introductions, price and volume - are positive for the month," said Sheetal Sapale, vice president-commercial at PharmaTrac...
The Indian pharma market has recorded unit growth of 2.2% in December, which remains to be small, Sapale said.. (Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)..
You might be interested in
GSK's Augmentin is India's no.1 drug brand
09, Dec, 23Research firm PharmaTrac data shows Augmentin sales at Rs 801 crore from November 2022-23. For the month of November, Augmentin sales stood at Rs 75 crore. It has shown a moving annual total (MAT) growth growth of 12.3%. As per the data, Glycomet GP sales stood at Rs 774 crore from same period and the sales for November stood at Rs 64 crore. It has shown a MAT growth of 7.5%.
Respiratory drug Foracort No. 1 in sales
18, Jan, 24India Business News: NEW DELHI: The deadly cocktail of growing pollution and smog seems to be choking us immensely.